Ortho Clinical Diagnostics
100 Indigo Creek Drive
Rochester
New York
14626
United States
Tel: 800-828-6316
Fax: 585-453-3660
Website: http://www.orthoclinical.com/
121 articles about Ortho Clinical Diagnostics
-
Ortho Clinical Diagnostics and Quest Diagnostics to Broaden Availability of COVID-19 Antibody Testing
5/11/2020
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today announced it is working with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to expand COVID-19 antibody testing to more than 20 Quest
-
Ortho Launches Second COVID-19 Antibody Test With 100% Specificity
4/26/2020
Ortho Clinical Diagnostics introduced and announced the U.S. Food and Drug Administration granted Emergency Use Authorization to its second COVID-19 antibody test—the VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 IgG Test.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
-
Antibody tests, also called serological tests, test if the individual has been exposed to SARS-CoV-2, the novel coronavirus that causes COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 15, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
-
COVID-19 Antibody Test Released by Ortho Clinical Diagnostics
4/3/2020
Aligned with its mission to improve and save lives with diagnostics, Ortho Clinical Diagnostics announced it is launching to market its SARS-CoV-2 antibody test—the VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack.
-
New VITROS® XT 3400 Chemistry System from Ortho Clinical Diagnostics Enhances Its VITROS® XT Solutions, Offering Labs Faster, More Accurate Results and Trusted System Reliability to Ensure Better Patient Outcomes
2/26/2020
Ortho Clinical Diagnostics, today announced the launch and availability of the VITROS® XT 3400 Chemistry System, which completes the company's VITROS® XT Solutions, a comprehensive suite of solutions that help labs obtain consistently fast, accurate and reliable results.
-
FDA Clears ORTHO™ Sera ID-MTS for Use on the ORTHO VISION® Analyzer
10/18/2019
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that ORTHO™ Sera, a suite of extended antigen phenotyping, has been cleared by the U.S. Food and Drug Administration for use on the ORTHO VISION® Analyzer.
-
Ortho Clinical Diagnostics Expands Drugs of Abuse and Therapeutic Drug Assay Menus in Collaboration With Thermo Fisher Scientific
10/15/2019
New MicroTip Partnership Assays (MPAs) Help Detect the Use of Fentanyl and Tricyclic Antidepressants (TCA)
-
Ortho Clinical Diagnostics to Demonstrate How Data Management Can Empower Labs During AABB Annual Meeting and Special Customer Event at Historic Sunset Station
10/15/2019
In Addition, Ortho to Celebrate 1,000 ORTHO VISION® Analyzers Installed in US Labs
-
Chris Smith Named Next Chief Executive Officer of Ortho Clinical Diagnostics
8/27/2019
Current Chairman and CEO Robert Yates to Step Down as CEO
-
Ortho Achieves Distinguished No. 1 Ranking for Service in Diagnostics Industry
8/6/2019
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that, for the fourth consecutive year, its Ortho Care™ service and support program was ranked No. 1 in the diagnostics industry.
-
Ortho to Share Research on Precision and Quality in Groundbreaking Lab Technology, Infectious Disease and Endocrinology at AACC 2019
8/5/2019
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced it will present four scientific posters and co-sponsor two posters at the 2019 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo.
-
Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure
7/23/2019
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac menu
-
Ortho Clinical Diagnostics, Lab Leaders, Executives to Examine How Data Is Transforming Labs and Health Care
7/10/2019
Ortho to Host Industry Conferences: 'Lab Leader Summit' and 'Healthcare Management in a Digital World'
-
Ortho Clinical Diagnostics to Present Research on Advances in Cardiac Testing, Diagnostics Technology at EuroMedLab 2019
5/16/2019
Educational Workshop and Posters to Focus on High-Sensitivity Troponin Assay Use and Performance, Lab Technology Innovations
-
Ortho Clinical Diagnostics to Host 4th Annual Hospital C-Suite Summit in Singapore
5/14/2019
2-Day Summit Will Bring Together Top Hospital Executives and Focus on Patient Safety and Service Excellence
-
Ortho's VITROS® High Sensitivity Troponin I Assay for the Diagnosis of Heart Attack Now CE Marked, Available in EU Countries
4/16/2019
Next-generation assay aids in diagnosing heart attacks faster and more accurately, and is enabled on the company's newest analyzer, the VITROS® XT 7600 Integrated System
-
FDA Clears VITROS® XT Chemistry Product Slides from Ortho Clinical Diagnostics
4/9/2019
Groundbreaking XT MicroSlides Deliver Accurate Results from 2 Simultaneous Miniaturized Tests, Simplifying Workflow and Improving Turnaround Time in the Lab